Summary
The regional brain distribution and binding of the antipsychotic benzamide drug remoxipride was studied in the male rat. After i.v. injections of3 H-remoxipride (1 μmol · kg−1) more than 85% of the radioactivity was identified as authentic remoxipride in brain by using reversed-phase liquid chromatography. Autoradiographic and spectroscopic analysis showed that3 H-remoxipride was distributed relatively even in different brain areas, with exception of the following structures, which showed highest drug concentrations: the choroid plexus, septum, medial part of the caudate nucleus, different areas of the thalamus and hypothalamus situated close to the cerebral ventricles. A closer analysis of the autoradiograms showed a gradient of radioactivity extending from the cerebral ventricles to the deeper parts of the brain at 30 minutes after injections. After 60 minutes radioactivity was detected throughout all forebrain dopamine receptive areas. These findings suggest that remoxipride enters the cerebrospinal fluid (CSF) via the vascular bed of the choroid plexus and that it enters the brain interstitial fluid from the CSF.
In the caudate nucleus, nucleus accumbens, olfactory tubercle and olfactory bulb 30–40% of the radioactivity was reduced by pretreatment with the dopamine D-2 selective drug raclopride. In addition, small, but significant, reductions (10–15%) of3H-remoxipride derived radioactivity was found in the neocortex, hippocampus and the cerebellum, suggesting that remoxipride interacts with a D-2 receptor also in these cortical structures.
Taken together, these studies show that after i.v. injections,3H-remoxipride enters the brain primarily in unmetabolized form when given in doses that affect DA receptor mediated behaviours, that it distributes to most areas throughout the neuraxis and that it binds to D-2 receptors in different parts of the basal ganglia, neocortex, hippocampus and cerebellum.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benakis A, Brown JPH, Benard P (1984) Autoradiography study of [14C]-sulpiride in monkey. Eur J Drug Metab Pharmacokinet 9: 365–370
Bischoff S, Bittiger H, Delini-Stula A, Ortmann R (1982) Septo-hippocampal system: target for substituted benzamides. Eur J Pharmacol 79: 225–232
Charuchinda C, Supavilai P, Karobath M, Palacios J (1987) Dopamine D-2 receptors in the rat brain: autoradiographic visulization using a high affinity selective agonist ligand. J Neurosci 7: 1352–1360
Chouinard G, Turnier L (1986) An early phase II clinical trial of remoxipride in schizophrenia with plasma neuroleptic activity. Psychopharmacol Bull 22: 267–271
Cohen JD, van Putten T, Marder S, Berger PA, Stahl SM (1987) The efficacy of piquindone, a new atypical neuroleptic in the treatment of positive and negative symptoms of schizophrenia. J Clin Psychopharmacol 7: 324–329
Gawell L, Hall H., Köhler Ch (1985) Preparation of tritium labelled benzamide dopamine D-2 ligands at high specific activity. J Labelled Comp 22: 1033–1043
Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin S2 and dopamine D2 antagonistic properties. J Pharmacol Exp Ther 244: 685–693
Köhler Ch, Ögren S-O, Haglund L, Ängeby T (1979) Regional displacement by sulpiride of [3 H]-spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action on limbic and nigral dopamine receptors. Neurosci Lett 13: 51–66
Köhler Ch, Fuxe K, Ross SB (1981a) Regional in vivo binding of [3H]N-n-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. Eur J Pharmacol 72: 397–402
Köhler Ch, Haglund L, Ögren S-O, Ängeby K (1981b) Regional blockade by neuroleptic drugs of in vivo [3 H]-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies. J Neural Transm 52: 163–173
Köhler Ch, Ögren S-O, Fuxe K (1984) Studies on the mechanism of action of substituted benzamide drugs. Acta Physiol Scand 69: 125–138
Köhler Ch, Hall H, Ögren S-O, Gawell L (1985) Specific in vitro and in vivo binding of [3H]-raclopride, a potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34: 2251–2259
Köhler Ch, Hall H, Gawell L (1986) Regional in vivo binding of the substituted benzamide [3H]-eticlopride in the rat brain. Evidence for the selective labelling of dopamine receptors. Eur J Pharmacol 120: 217–226
Köhler Ch, Karlsson-Boethius G (1988) In vivo labelling of rat brain dopamine D-2 receptors; stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of3H-spiperone,3H-N,N-propylnorapomorphine and3H-raclopride binding in the rat brain. J Neural Transm 73: 87–100
Köhler Ch, Hall H, Magnusson O, Lewander T, Gustafsson K (1990) Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatr Scand 82: 27–36
Lindström L, Besev G, Stening G, Widerlöv E (1985) An open study of remoxipride, a benzamide derivate in schizophrenia. Psychopharmacology 86: 242–243
Ljungberg T, Ungerstedt U (1978) Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action. Psychopharmacology 56: 239–247
Lowe IA, Seeger TF, Vinivk FJ (1988) Atypical antipsychotics — Recent findings and new perspectives. Med Res Rev 8: 475–497
McLean S, Weber E (1988) Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea pig brain. Neuroscience 25: 259–269
Meltzer HY, So R, Miller RJ, Fang VS (1979) Comparison of the effects of substituted and standard neuroleptic on the binding of [3H]-spiroperidol in the rat pituitary and striatum with “in vivo” effects of rat prolactin secretion. Life Sci 25: 573–584
Meltzer HY (1990) Clozapine: mechanism of action in relationship to its clinical advantages. In: Kales A, Stefanos CN, Talbott IA (eds) Recent advances in schizophrenia (in press)
Nilsson LB (1990) Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography. J Chromatogr 526: 139–150
Ögren S-O, Hall H, Köhler Ch, Magnusson O, Lindbom L-O, Ängeby T, Florvall L (1984) Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain. Eur J Pharmacol 102: 459–474
Ögren S-O, Hall H, Köhler Ch, Magnusson O, Sjöstrand S-E (1986) The selective dopamine D-2 receptor antagonist raclopride discriminates between dopamine mediated functions. Psychopharmacology 90: 287–294
Ögren S-O, Florvall L, Hall H, Magnusson O, Ängeby-Möller K (1990) Neuropharmacological and behavioural properties or remoxipride in the rat. Acta Psychiatr Scand 82: 21–27
Ögren S-O, Höberg T (1988) Novel dopamine D-2 antagonists for the treatment of schizophrenia. ISI Atlas of Science 2: 141–147
Patris M, Aqussol P, Alby JM, Brion S, Buinat G, Castelnau D, Deluermoz H, Dufour M, Ferreri M, Goudelmand M, Legnay D, Lampiere T, Martin A, Morin D, Tignol J, Vincent T, Albaret C (1990) A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Acta Psychiatr Scand 358, 82: 78–83
Wadworth AN, Hell RC (1990) Remoxipride: a review of its pharmacodynamic and pharmacocinetic properties and therapeutic potential in schizophrenia. Drugs 40: 863–879
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Köhler, C., Radesäter, A.C., Karlsson-Boethius, G. et al. Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain. J. Neural Transmission 87, 49–62 (1992). https://doi.org/10.1007/BF01253110
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01253110